Prospective Randomized Controlled Study of Interferon-Alpha in Preventing Hepatocellular Carcinoma Recurrence after Medical Ablation Therapy for Primary Tumors

Cancer

Volumn 100, Issue 2, 2004, Pages 376-382

  Lin, Shi Ming ^a   Lin, Chun Jung ^a   Hsu, Chao Wei ^a   Tai, Dar In ^a   Sheen, I Shyan ^a   Lin, Deng Yn ^a   Liaw, Yun Fan ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Hepatocellular carcinoma (HCC); Interferon (IFN ); Medical ablation therapy; Recurrence

Indexed keywords

ALPHA INTERFERON;

ARTHRALGIA; ARTICLE; CANCER PREVENTION; CANCER RECURRENCE; CANCER THERAPY; CATHETER ABLATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REGIMEN; DRUG EFFICACY; FEVER; FOLLOW UP; HEADACHE; HUMAN; LIVER CELL CARCINOMA; MALAISE; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

AGED; CARCINOMA, HEPATOCELLULAR; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 0346093899     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20004     Document Type: Article

References (25)

1. Teo EK, Fock KM. Hepatocellular carcinoma: an Asian perspective. Dig Dis. 2001;19:263-268.
2. Tai DI, Chen CH, Chang TT, et al. Survival of relatives of patients with hepatocellular carcinoma. Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: role of viral infection. J Gastroenterol Hepatol. 2002;17:682-689.
3. Livraghi T, Giorgio A, Mann G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology. 1995;197:101-108.
4. Ohnishi K, Nomura F, Ito S, Fujiwara K. Prognosis of small hepatocellular carcinoma (less than 3 cm) after percutaneous acetic acid injection: study of 91 cases. Hepatology. 1996;23:994-1002.
5. McGahan JP, Dodd GD. Radiofrequency ablation of the liver: current status. A J R Am J Roentgenol. 2001;176:3-16.
6. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinoma: a retrospective and nation wide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32:1224-1229.
7. Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - a randomized controlled trial. Gastroenterology. 1988;94:453-456.
8. Lin SM, Lin DY, Lin CJ. Percutaneous ethanol injection therapy in 47 cirrhotic patients with hepatocellular carcinoma 5 cm or less: a long-term result. Int J Clin Pract. 1999;53:257-262.
9. Lin SM, Kuo SH, Lin DY, Lin CJ, Shen CH. Cytologic changes in hepatocellular carcinoma after percutaneous acetic acid injection. Correlation with helical computed tomography findings. Acta Cytol. 2000;44:1-6.
10. Collconi M, Buzzoni R, Bajetta E, et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer. 1993;72:3196-3201.
11. Kardinal CG, Moertel CG, Wieand HS, et al. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma. Cancer. 1993;71:2187-2190.
12. Sachs E, Di Bisceglie AM, Dusheiko GM, et al. Treatment of hepatocellular carcinoma with recombinant leukocyte interferon: pilot study. Br J Cancer. 1985;52:105-109.
13. Ikeda K, Saitoh S, Suzuki Y, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus. A pilot study. Cancer. 1998;82:827-835.
14. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971-975.
15. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996;24:141-147.
16. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of effects on interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051-1055.
17. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alfa therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma: a randomized, controlled trial. Ann Intern Med. 2001;134:963-967.
18. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32:228-232.
19. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138:299-306.
20. Oon CJ. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol. 1992;31S:S137-S142.
21. Liaw YF, Shen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HbsAg in chronic hepatitis B virus infection: a prospective study. Hepatology. 1991;13:627-631.
22. Cox DR. Regression model and life tables. J R Stat Soc [B]. 1972;34:187-220.
23. SAS Institute Inc. SAS/STAT user's guide, release 6.11 edition. Cary, NC: SAS, 1996.
24. Lin SM, Lin CJ, Chung HJ, Hsu CW, Peng CY. Power rolloff during interactive radiofrequency ablation can enhance necrosis when treating hepatocellular carcinoma. A J R Am J Roentgenol. 2003;180:151-157.
25. Ko S, Nakajima Y, Kanehiro H, et al. Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Results of multivariate analysis. Ann Surg. 1996;224:591-595.